by treating cells with leupeptin or with the broad spectrum cysteine protease inhibitor E64 .
Here, we show that the general serine protease inhibitor 4-(2-aminoethyl)-benzenesulfonyl fluoride (AEBSF) (Kazmirowski, 1971) strongly and reproducibly decreases A␤ production in a variety of different cell types, while p3 production is unaffected or increased. We demonstrate that this inhibition occurs only in cells that produce A␤ starting at Asp1, not in cells producing A␤-related proteins starting predominantly at other N-termini. We hypothesize that AEBSF directly inactivates a serine protease type ␤-secretase enzyme that cleaves at Met-Asp to generate the conventional N-terminus of A␤.
Results

AEBSF Inhibits A␤ Production in a Variety of Cell Lines
K293 human embryonic kidney cells stably transfected with ␤APP 695 carrying the Swedish mutation (K695sw) were metabolically labeled for 2 hr and chased for 2 hr in the presence of increasing concentrations of AEBSF. To exclude differential degradation of secreted material after collection of the treated versus untreated media, all media were brought to a final concentration of 1 mM AEBSF immediately after the 2 hr chase. Media were then immunoprecipitated with the A␤ (1-40) specific polyclonal antibody R1282. A dose-dependent decrease Table 1 ). In these cells, AEBSF led to an increase in p3 levels.
To determine how general the inhibition of A␤ production was, we studied three additional cell lines. HS695, shift the cleavage to another position, indicating that ␤-secretase exhibits high-sequence specificity. A typia human glioma cell line, and SKN695, a human neuroblastoma cell line, were each stably transfected with cal mutation of this class, D597⌬, not only eliminates the Asp1 protein but leads to significant production of wild-type ␤APP 695 . In addition, primary human skin fibroblasts cultured from a subject carrying the Swedish an A␤ species starting at Phe4 (Citron et al., 1995).
For both ␣-and ␤-secretases, a wide variety of candi-␤APP mutation were studied. All three of these cell lines showed the same qualitative effect of AEBSF, i.e., a date proteases have been suggested, largely based on their ability to cleave synthetic substrates that mimic dose-dependent decrease of A␤ production. However, the IC50 was substantially lower than 1 mM, generally the native APP cleavage site (for review, see Evin et al., 1994) . The physiological relevance of these candidate in the ‫ف‬ 300 M range, for both HS695 and SKN695 (Figures 2C and 2D ; Table 1 ). In general, p3 was constant enzymes has not been demonstrated, for example, by inhibiting their enzymatic activity in intact cells and or increased, however, in the more sensitive HS695 line, doses of AEBSF above the IC50 for A␤ led to a decrease showing a corresponding decrease in A␤ or p3 production. An inhibitor that acts directly on the production of in p3 production, as well ( Figure 2C ). In the primary Swedish fibroblasts, almost no p3 was observed without A␤ or p3 in intact living cells would be highly useful for isolating and characterizing the relevant proteases drug treatment ( Figure 2E ), as has been described previously (Citron et al., 1994). Wild-type primary fibroblasts involved in ␤APP processing. Previous studies have already demonstrated that A␤ production is not affected also showed an inhibition of A␤ and an increase in p3 as well as in immature N'-glycosylated ␤APP, and showed some increase in the 10 kDa C-terminal fragment. (Figure 3 ; Table 1 ). These data suggest that AEBSF inhibits intracellular degradation of ␤APP and its ␣-secretase generated C-terminal fragment. The strong increase in immature N'-glycosylated ␤APP 695 suggests that a major proportion of this species is normally degraded intracellularly before becoming fully O-glycosylated.
AEBSF Increases ␣-Secretion but Inhibits ␤-Secretion of APPs
To exclude the possibility that the observed decrease of A␤ levels was due to a general, nonspecific inhibition of protein secretion, aliquots of the total conditioned media used for the dose response experiment with K695sw cells were run on a gel without immunoprecipitation. Increasing doses of AEBSF did not alter the re- Table  2 ). However, ␤-APP s (precipitated by 192sw) was clearly transfected with APP 695 sw (K695sw) would be expected to show a more pronounced decrease in total A␤ than decreased ( Figure 5B ; Table 2), as was A␤, while p3 was increased ( Figure 5C ; Table 2 ). The 12 kDa fragment K293 cells transfected with wild-type APP 695 since in K695sw cells, the N-terminus of A␤ has been shown to was assessed by precipitating it from cell lysates using the A␤ antibody 1282 ( Figure 5D ). The N-terminal sestart exclusively at Asp 1 (Citron et al., 1994), whereas in K695 cells, which express wild-type APP, about 20% quence of this band has previously been confirmed by radiosequencing, indicating that it starts at Asp1 (data of the total A␤ species generated begins at positions other than Asp 1 (Haass et al., 1992b), presumably as not shown). Interestingly, 1282 did not precipitate the 10 kDa fragment (Figure 5D ), which often overshadows a result of cleavages by different proteases (Citron et al., 1995). Thus, compensatory cleavage by these uninthe 12 kDa fragment in C7 precipitations ( Figure 5E ). In the presence of AEBSF, the 12 kDa fragment was hibited proteases could account for the relatively modest A␤ decline observed in K695 cells after AEBSF comstrongly reduced ( Figure 5D ; Table 2 ), while the 10 kDa fragment and full-length APP were not decreased (Figpared to the other cell lines examined above (Table 1) , all of which show almost exclusively Asp 1 cleavage ure 5E; Table 2 ). Taken together, these data demonstrate (for review, see Selkoe, 1994). Therefore, interest is Of particular importance are the results of radioonstrate its inhibition under biologically relevant conditions, i.e., in intact human cells. Here, we report that the sequencing of secreted A␤, which show that AEBSF specifically inhibits the protease(s) capable of generatserine protease inhibitor, AEBSF, decreases the secretion of A␤ by five different cell types, including three ing A␤ peptides starting at Asp1. This specificity was demonstrated by the observation that AEBSF inhibited human cell lines and primary fibroblasts cultured from normal subjects, and from AD patients harboring a ␤APP production of the major A␤ peptide beginning at Asp 1, resulting in enhanced production of A␤-like proteins missense mutation. This decrease in secretion is due to a decrease in A␤ production, not a block in release, beginning at alternative N-termini. Although AEBSF is clearly a broad spectrum serine-protease inhibitor, it because extracts of treated cells do not show any accumulation of A␤ intracellularly ( Figure 5D) .
shows a differential effect on the several as yet undefined proteolytic activities (␤-secretases) that constituAnalysis of the production of full-length ␤APP and its principal proteolytic derivatives shows that AEBSF does tively process ␤APP holoproteins at or near the A␤ N-terminus. The most straightforward explanation for not lower A␤ by a nonspecific or cytotoxic mechanism, because the levels of full-length ␤APP are stabilized and the effects reported here is that AEBSF selectively inhibits a ␤-secretase activity that cleaves the Met-Asp bond the secretion of ␣-secretase-generated products, i.e., ␣-APPs and p3, is not decreased, whereas ␤-secretase at the N-terminus of A␤. In particular, using K695sw cells, we could demonstrate a decrease not only in A␤ cleavage products are reduced. Importantly, the secretion of proteins in general is not reduced by AEBSF but also in the direct products of Met-Asp-␤-secretase cleavage, namely ␤-APP s and the 12 kDa fragment. In under the conditions of our experiments. The striking increase in full-length APP and ␣-APP s by AEBSF sugseveral cell lines, we observed a concomitant increase of alternative ␤-secretase-like N-terminal cleavages, gests that in normal cells, a major portion of full-length , because the PKC inhibitor staurosporine does cleaving ␤-secretase is a highly sequence-specific protease that is unlikely to be responsible for creating the not reverse the effect of AEBSF (data not shown). In this work, AEBSF has been used only in the most informative alternative A␤ N-termini observed in some cell types (Citron et al., 1995) . In the majority of cell types examined pulse chase format to focus on APP-processing effects. Continuous labeling in the presence of the compound that almost exclusively produce A␤ beginning at Asp 1, AEBSF causes only a decrease in total A␤ secretion.
leads to a decrease in all APP metabolites (data not shown), probably due to some general interference with Presumably, such cell types lack the proteases or trafficking mechanisms necessary to generate alternative synthesis of the protein. The short pulse chase used for K695sw clearly demonstrates that all ␤-secretase-A␤ N-termini, even when the major N-terminal cleavage is prevented. The enhanced production of ␣-secretasecleavage products are reduced and does not show any accumulation of intracellular A␤, therefore ruling out the mediated products of ␤APP that AEBSF induces suggests that inhibition of the major ␤-secretase (and other possibility that AEBSF only interferes with secretion of A␤ into the medium rather than its production by serine proteases) provides more ␤APP substrate for ␣-secretase cleavage.
␤-secretase cleavage. However, this still leaves open the possibility that AEBSF inhibits a serine protease that Although the selective inhibition of a Met-Asp-cleaving ␤-secretase activity by AEBSF is consistent with proteolytically activates ␤-secretase. We believe this possibility is unlikely, because ␤-secretase appears to the data reported here, we cannot exclude alternative mechanisms. For example, it is possible that inhibition be constitutively active, requiring us to postulate a very short half life of an activated ␤-secretase, since AEBSF of serine proteases by AEBSF, or another action of this compound, could alter ␤APP trafficking rather than diacts within 20 min in our experiments. It is important to emphasize that AEBSF itself or rerectly inhibiting the Met-Asp-␤-secretase activity. However, we have at least ruled out the possibility that lated compounds would be unlikely to be pharmaceutically useful for A␤ inhibition in vivo, given their nonspe-AEBSF reduces A␤ production by protein kinase C (PKC) activation, as has been described for phorbolesters and cificity and multiple cellular actions. Nonetheless, the 
